Sam Altman's Retro Biosciences Aims to Launch Anti-Aging Brain Pill by 2025: What This Means for Longevity Tech
OpenAI CEO Sam Altman’s secretive longevity startup, Retro Biosciences, is making waves in the anti-aging space with plans to launch its first commercial product as early as 2025. The company, which received a staggering $180 million investment from Altman, is developing a brain-focused supplement designed to enhance cognitive function and potentially extend human healthspan. This move represents one of the first tangible consumer products to emerge from the billionaire’s ambitious longevity investments, signaling a shift from theoretical research to practical applications in the anti-aging market.
Continue reading